MALT Lymphoma
Conditions
Keywords
MALT lymphoma, Advanced or Helicobacter pylori-refractory MALT lymphoma
Brief summary
The activity of monotherapy with Lenalidomide will be evaluated in patients with lymphoma of the mucosa associated lymphoid tissue (MALT).
Detailed description
The primary objective of the study is to evaluate the clinical potential of Lenalidomide to induce objective/histologic responses in patients with MALT lymphoma. The secondary objectives are to evaluate the safety of Lenalidomide in this patient population and to evaluate the impact of Lenalidomide on progression free survival.
Interventions
DRUGLenalidomide
25 mg Lenalidomide p.o. daily for 21 days
Sponsors
Medical University of Vienna
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with histologically confirmed MALT lymphoma with measurable disease (stage I - IV) * With first or greater relapse after HP-eradication, radiation or chemotherapy in case of gastric lymphoma * Age \> 18 years * Must be able to tolerate therapy, and have adequate cardiac, renal, and hepatic function, ECOG status of 0 - 2 * Must be capable of understanding the purpose of the study and have given written informed consent
Exclusion criteria
* Lymphoma histology other than MALT lymphoma or MALT lymphoma with a diffuse large cell lymphoma (high grade lymphoma) - component * Use of any investigational agent within 28 days prior to initiation of treatment with lenalidomide * History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 5 years * Major surgery, other than diagnostic surgery, within the last 4 weeks * Evidence of CNS involvement * A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs * Severe peripheral polyneuropathy * Clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 6 months * Inadequate hematological status at baseline prior to study entry: Dependency on red blood cell and/or platelet transfusions, ANC (absolute neutrophil count (segmented + bands)) \< 1.0 x 109/L * Patients with active opportunistic infections * Pregnancy * Uncontrolled diabetes mellitus * Preexisting thromboembolic events at start of study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of objective responses induced by Lenalidomide | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression | 24 months |
Countries
Austria
Contacts
Primary ContactMarkus Raderer, MD
Outcome results
None listed